Wistar Institute Melanoma (WM) PDX Models

Inotiv offers the Wistar Institute Melanoma (WM) PDX model collection established from targeted therapy relapsed melanoma patients, spanning BRAF inhibitors, BRAK/MEK inhibitors, immune checkpoint inhibitors and targeted therapy and immunotherapy (TT/IT) combinations. Narrow down the cells that are right for your study below.

Wistar Institute Melanoma (WM) PDX models

Number	Age / Gender	Details
WM4070-1	59 F	Biopsy site: SQ Primary tumor type: Unknown primary Stage at Bx: IV Targeted therapy prior to Bx: None Immune therapy prior to Bx: None Mutation: BRAFV600K RPPA: 76, submitted
WM4237	28 F	Biopsy site: BRAIN Primary tumor type: Unknown primary Stage at Bx: IV Targeted therapy prior to Bx: None Immune therapy prior to Bx: Ipilimumab , PD Mutation: BRAFV600E RPPA: 102
WM3965-2	37 F	Biopsy site: PAROTID Primary tumor type: SSM Stage at Bx: IV Targeted therapy prior to Bx: vemurafenib, PR, PFS 14.7 weeks, OS 61.1 weeks Immune therapy prior to Bx: None Mutation: BRAFV600E RPPA: 76,96, submitted Notes: Krepler et al., 2016 Clin Cancer Res; 22(7) April 1, 2016. Per CK: BRAF-R= BRAF-Resistant, probably the most popular, treated with Standard of Care targeted therapy.
WM4071-1	77 M	Biopsy site: MET Primary tumor type: MULTIPLE PRIMARIES Stage at Bx: IV Targeted therapy prior to Bx: vemurafenib, mixed response, PFS 46.7 weeks, OS 58.7 weeks Immune therapy prior to Bx: None Mutation: BRAFV600E RPPA: 76,83, submitted Notes: Krepler et al., 2016 Clin Cancer Res; 22(7) April 1, 2016. Per CK: BRAF-R= BRAF-Resistant, probably the most popular, treated with Standard of Care targeted therapy.
WM4071-2	77 M	Biopsy site: BRAIN Primary tumor type: MULTIPLE PRIMARIES Stage at Bx: IV Targeted therapy prior to Bx: vemurafenib, mixed response, PFS 46.7 weeks, OS 58.7 weeks Immune therapy prior to Bx: None Mutation: BRAFV600E RPPA: 76,83, submitted Notes: Krepler et al., 2016 Clin Cancer Res; 22(7) April 1, 2016. Per CK: BRAF-R= BRAF-Resistant, probably the most popular, treated with Standard of Care targeted therapy.
WM3983	93 F	Biopsy site: SQ Primary tumor type: SSM Stage at Bx: IV Targeted therapy prior to Bx: vemurafenib, isolated progression, PFS 29.6 weeks, OS 86 weeks Immune therapy prior to Bx: None Mutation: BRAFV600K NRASQ61K RPPA: 70,76,96, submitted Notes: Krepler et al., 2016 Clin Cancer Res; 22(7) April 1, 2016. Per CK: BRAF-R= BRAF-Resistant, probably the most popular, treated with Standard of Care targeted therapy.
WM3974	63 F	Biopsy site: SQ Primary tumor type: MUCOSAL Stage at Bx: IV Targeted therapy prior to Bx: Dasatinib, PR Immune therapy prior to Bx: None Mutation: NRAS G12A KIT L576P RPPA: 102
WM4208	53 M	Biopsy site: LN Primary tumor type: NMM Stage at Bx: IV Targeted therapy prior to Bx: None Immune therapy prior to Bx: Ipilimumab, PD Mutation: NRASQ61R RPPA: 102
WM4224	75 M	Biopsy site: LN Primary tumor type: NMM Stage at Bx: IIIB Targeted therapy prior to Bx: None Immune therapy prior to Bx: Ipilimumab, PR Mutation: NRASQ61R RPPA: 102
WM4099	62 F	Biopsy site: SQ Primary tumor type: SSM Stage at Bx: IV Targeted therapy prior to Bx: None Immune therapy prior to Bx: Ipilimumab, d/c due to toxicity Mutation: NF1 Q1341X RPPA: NA
WM3921	61 M	Biopsy site: MET Primary tumor type: Amelanotic Stage at Bx: IV Targeted therapy prior to Bx: None Immune therapy prior to Bx: None Mutation: WT RPPA: NA

Order today

Wistar Institute Melanoma (WM) PDX models

Subscribe to updates from Inotiv